MOLOGNI LUCA

Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante Varillas, S. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. PLOS ONE, 20(1) [10.1371/journal.pone.0308747]. Detail

Malighetti, F., Villa, M., Villa, A., Pelucchi, S., Aroldi, A., Cortinovis, D., et al. (2025). Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 26(5) [10.3390/ijms26051943]. Detail

Crippa, V., Fontana, D., Civettini, I., Mologni, L., Piazza, R., Gambacorti Passerini, C., et al. (2024). Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer. Intervento presentato a: AACR Annual Meeting 2024 - April 5 - 10, 2024, San Diego, Ca, Usa. Detail

Civettini, I., Zappaterra, A., Corti, P., Messina, A., Aroldi, A., Biondi, A., et al. (2024). Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype. MED [10.1016/j.medj.2024.11.007]. Detail

Malighetti, F., Villa, M., Mauri, M., Piane, S., Crippa, V., Crespiatico, I., et al. (2024). Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies. BIOMEDICINES, 12(12) [10.3390/biomedicines12122819]. Detail